merck rsv - Search News

News

Merck, FDA and RSV

CNBC on MSN · 3d

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Reuters on MSN · 2d

US FDA approves Merck's RSV antibody for infants

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said.

FDA Approves Merck’s Enflonsia to prevent RSV in infants

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial virus, or RSV, a common but potentially serious seasonal illness.

2don MSN

Newly approved therapy could offer another option for protecting infants from RSV, a common infection that can be deadly

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

3h

New antibody shot could help protect babies from RSV

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

Fierce Pharma3d

Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Sanofi starts shipping RSV drug early as rival nears market

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results